ATOSSA THERAPEUTICS, INC.
About ATOSSA THERAPEUTICS, INC.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2015
- $1.8K
- Net income
- -$34.8M
- Total assets
- $47.6M
- Market cap
- $38.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $37.1M
- Operating income
- -$37.1M
- Income tax
- $0
- Net income
- -$34.8M
- EPS (basic)
- $-4.04
- EPS (diluted)
- $-4.04
Balance sheet
- Total assets
- $47.6M
- Current assets
- $45.6M
- Total liabilities
- $8.3M
- Current liabilities
- $8.3M
- Shareholders’ equity
- $39.4M
Cash flow
- Operating cash flow
- -$29.8M
- Investing cash flow
- -$23.0K
- Financing cash flow
- $29.8M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $38.5M
- EPS (diluted)
- $-4.04
- Shares outstanding
- 8.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 8, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $34.8M in FY2015.
- Trading 74% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ATOSSA THERAPEUTICS, INC..
Write a review
News about ATOSSA THERAPEUTICS, INC.
News & sentiment via Polygon.io
